2023
Aiming for the cure in myeloma: Putting our best foot forward
Bar N, Firestone R, Usmani S. Aiming for the cure in myeloma: Putting our best foot forward. Blood Reviews 2023, 62: 101116. PMID: 37596172, DOI: 10.1016/j.blre.2023.101116.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsHumansMultiple MyelomaTransplantation, AutologousConceptsMultiple myelomaMinimal residual disease negativityDeeper response ratesResponse-adapted strategyDuration of therapyPowerful prognostic factorSignificant inter-patient variabilityNovel clinical trialsInter-patient variabilityRegimen compositionFrontline therapyUpfront therapyPrognostic factorsMyeloma patientsMyeloma treatmentClinical trialsTreatment strategiesCurrent relevant literatureTreatment approachesResponse rateDisease riskTherapyMyelomaUse of transplantsCurrent standard
2021
Autologous hematopoietic stem cell product contaminated with Salmonella due to occult salmonellosis in an asymptomatic donor
Jacobs JW, Guarente J, Hendrickson JE, Tormey CA, Bar N. Autologous hematopoietic stem cell product contaminated with Salmonella due to occult salmonellosis in an asymptomatic donor. Journal Of Clinical Apheresis 2021, 37: 316-319. PMID: 34953078, DOI: 10.1002/jca.21962.Peer-Reviewed Original ResearchMeSH KeywordsHematopoietic Stem Cell TransplantationHematopoietic Stem CellsHumansSalmonellaSalmonella InfectionsTransplantation, AutologousConceptsCellular therapy productsHematopoietic stem cellsAllogeneic blood productsAutologous hematopoietic stem cellsHematopoietic stem cell productsPathogenic Gram-negative organismsNormal skin floraTherapy productsCase of SalmonellaStem cell productsGram-negative organismsAsymptomatic donorsTherapeutic dilemmaBlood productsPathogen reduction technologySkin floraHSC productsAdverse effectsCell productsPrior reportsSignificant reductionStem cellsSalmonellosisSalmonella bacteriaMost microorganisms